Johns Hopkins Medicine Johns Hopkins Logo
make a gift
hopkins urology on you tube  twitter urology department at hopkins   facebook urology department at hopkins  blog urology department at hopkins  
                
   
Misop Han, M.D. NASERUDDIN HÖTI, Ph.D.
Instructor
Department of Urology, Johns Hopkins University School of Medicine

Email:nhoti1@jhmi.edu

RESEARCH AND PROFESSIONAL EXPERIENCE
Prostate cancer affects one in six men and is the second leading cause of cancer death among men in the United States. Conventional therapies may lead to resistant cancer which is merely managed and not cured. Gene therapy using Adenoviral vectors have shown promise as a treatment strategy that can target both localized and metastatic prostate cancer.

The main mission of our group is to translate advances in imaging, oncology, and virology into innovative gene therapy based cancer therapeutics. Using molecular techniques to specifically re-target the viral vector to prostate cancer cells as well as shortening the life cycle of these viruses in order to invade and kill the tumor before they are cleared from the body.

EDUCATION

Under Construction

PUBLICATIONS

 

  1. Naseruddin Höti, Zhu DE, Song Z, Wu Z, Tabassum S, Wu M p53-dependent apoptotic mechanism of a newdesigner bimetallic compound tri-phenyl tin benzimidazolethiol copper chloride (TPT-CuCl2): in vivo studies inWistar rats as well as in vitro studies in human cervical cancer cells. J Pharmacol Exp Ther. (2004) 1:22-33

  2. Song Z, Liu S, He H, Höti N, Wang Y, Feng S, Wu M A single amino acid change (Asp 53 --> Ala53) convertsSurvivin from anti-apoptotic to pro-apoptotic. Mol.Biol.Cell. (2004)1287-96

  3. Naseruddin Höti, Jun Ma, Tabasum S, Yi Wang, and Mian Wu*Triphenyl tin benzimidazolethiol, a novel antitumor agent induces mitochondrial-mediated apoptosis in human cervical cancer via suppression of HPV-18 encoded E6” Journal of Biochemistry(2003) Oct;4:521-8

  4. B.Ren, N.Höti, X.Rabasseda,Y.Z Wang and M.Wu “The Antiangiogenic and Therapeutic Implication of Endostatin” Journal of Methods Find Exp Clin Pharmocol2003, 25(3):215-224.

  5. De-e Zhu, Naseruddin Höti, Zhiyin Song, Lei Jin, ZhengSheng Wu, Qiang Wu, and Mian Wu,*Suppression of tumor growth using a recombinant Adenoviral vector carrying the dominant negative mutant gene Survivin-D53A in a nude mice model Cancer Gene therapy2006 Aug;13(8):762-70). (Co-First authors)

  6. Xia Q, Chowdhury W  Chen CL, Carducci M, Höti N , Shabbeer S and *Ronald Rodriguez Chronic, But Not Acute, Administration of Valproic Acid Inhibits Prostate Cancer Cell Growth in vitro Cancer Research2006;66(14):7237-44.

  7. Naseruddin Höti, Shawn E. Lupold, Wasim Chowdhury, Ronald Rodriguez* “Valporic acid a Histone Deacetylase Inhibitor Is an Antagonist for Oncolytic Adenoviral Gene Therapy” Molecular Therapy2006 Dec;14(6):768-78.

  8. Naseruddin Höti and Ronald Rodriguez Gene Therapy for the prostate Cancer” AUANews Nov 2005, page 12. Review article

  9. Naseruddin.Höti Ying Lia, Chien-Lun Chen, David C. Johns, Qinghua Xia ,Arup Kabul , Jer-Tsong Hsieh and Ronald Rodriguez* Androgen Receptor attenuation of Ad5 replication: implications for the development of conditionally replication competent Adenoviruses. Molecular Therapy 2007 Aug;15(8):1495-503

  10. Feng S, Yang Y, Mei Y, Ma L, Zhu DE, Höti N, Castanares M, Wu M*.Cleavage of RIP3 inactivates its caspase-independent apoptosis pathway by removal of kinase domain. Cell Signal. 2007 Oct;19(10):2056-67

  11. Siraj Sami, Naseruddin Höti, Han-Mei Xu, Zilong Shen, Xiaofeng Huang Valproic acid inhibits the growth of cervical cancer both in vitro and in vivo. Journal of Biochemistry(2008 Sep;144(3):357-62

  12. Naseruddin Höti, Sadaf Musfata, Wasim Chowdhury, Shawn E. Lupold, Ronald Rodriguez*
    Host Defense Turned Viral Offense, Prostate specific CRAds using RNA interference. (Manuscript in Revision)

MEMBERSHIP IN PROFESSIONAL ORGANIZATIONS

  • 2004-Present American Society of Gene Therapy; Associate Member

  • 2004-Present American Association for Cancer Research; Associate Member

  • 2010- American Association for the Advancement of Science (AAAS)

AWARDS & HONORS

  1. FAMRI Young Clinical Scientist Award (YCSA) 2009-2011 Boston Massachusett USA

  2. Wendy Will Case Cancer Award, CHICAGO, ILLINOIS 60603 (2010)

  3. Short Term Max Planck Visiting Fellowship Award (2004) Dresden Germany

  4. Merit scholarship in College (Top 15 students out of 100 students)

  5. Full funded Ph.D Scholarship from the China Scholarship Council (CSC) and Ministry of Education Pakistan (MOE)

  6. Full funded Merit Scholarship from the University of the Punjab Pakistan. (Distinction in M.Phil, Top the M.Phil session of 1999-2001)

  7. Merit Scholarship in Undergraduate Level University of Agriculture Pakistan

PATENTS

Armoring CRAd with shRNA against p21/Waf-1---The next generation of oncolytic adenoviruses (ROI filed By Johns Hopkins School of Medicine)

   CONTACT INFORMATION

 

  • Address:
    600 N. Wolfe St., Park Building, Room 202C
    Baltimore, MD 21287




© The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System. All rights reserved.| Disclaimer
Email: webmaster@urology.jhu.edu | 600 North Wolfe Street, Baltimore, Maryland 21287